Document Classification

Section Type: RESULTS

Text: At 12 months, patients treated with ranibizumab (0. 3 mg [n = 137] or 0. 5 mg [n = 139]) had mean improvements in NEI VFQ-25 composite scores of 5. 9 (95 % confidence interval [CI], 3. 6 to 8. 3) and 8. 1 (95 % CI, 5. 3 to 10. 8) points, respectively ; patients treated with PDT (n = 142) had a mean improvement of 2. 2 points (95 % CI, -0. 3 to 4. 7 ; vs 0. 5 mg of ranibizumab, P <. 001 ; vs 0. 3 mg of ranibizumab, P =. 003).